Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Successful Multinational Corporations in China Series: Qualcomm China
Since China's reform and opening-up, many multinational corporations and groups have achieved success in China. They have not only been successful in their fields, but some also benefitted from wise M&A moves or investments. To answer these questions EqualOcean launches its Successful Multinational Corporations in China and analyzes the critical points of investing in China for investors and people interested in such a topic.
Yesterday 02:02 PM
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM